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Blood supply is essential for development and growth of tumors and angiogenesis is the fundamental process of new blood vessel
formation from preexisting ones. Angiogenesis is a prognostic indicator for a variety of tumors, and it coincides with increased
shedding of neoplastic cells into the circulation andmetastasis. Several molecules such as cell surface receptors, growth factors, and
enzymes are involved in this process. While antiangiogenic therapy for cancer has been proposed over 20 years ago, it has garnered
much controversy in recent years within the scientific community. The complex relationships between the angiogenic signaling
cascade and antiangiogenic substances have indicated the angiogenic pathway as a valid target for anticancer drug development and
VEGF has become the primary antiangiogenic drug target.This review discusses the basic and clinical perspectives of angiogenesis
highlighting the importance of comparative biology in understanding tumor angiogenesis and the integration of these model
systems for future drug development.
1. Introduction
Blood is essential for tumor growth and progression and
new vascular segments are needed to supply the growing
tumor mass with oxygen and nutrients. Different forms of
neovascularization are known, and the most important are
vasculogenesis (defined as de novo formation of a capillary
plexus by endothelial progenitor cells) [1]; angiogenesis
(formation of a new capillary network from preexisting
capillaries) [2]; vasculogenic mimicry (a special passage of
blood without endothelial cells) [3]; and vessel cooption
(a process where tumor cells initially coopt host blood
vasculature without inducing angiogenesis; the coopted host
vasculature regresses, leading to a secondary avascular tumor,
hypoxia, and robust angiogenesis at the tumor margin) [4].
Tumors can use all the different modes of vessel formation
and these different mechanisms may exist concomitantly in
the same tumor or may be selectively involved in a specific
tumor type or host environment [5].
It has been established that vasculogenesis occurs during
embryogenesis, when endothelial cells are born from pro-
genitor cell types [6], and also in the adult and particularly
during tumor vascularization [7]. Vasculogenesis in tumors
is de novo vessel formation by in situ incorporation, differ-
entiation, migration, and/or proliferation of bone marrow-
derived endothelial precursor cells [8, 9]. A wealth of evi-
dence indicates that tumor blood vessels differ significantly
from normal vessels in their structural organization and
endothelial properties. This finding suggests that tumor
vascularization depends on mechanisms distinct from the
simple recruitment from adjacent tissue of preexisting blood
vessels. The recapitulation of an embryonic-like vasculoge-
nesis may allow a de novo formation of vessels within the
tumor. This process involves endothelial differentiation of
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normal or malignant adult cells bearing stem and progenitor
properties leading to generation of endothelial cells with
abnormal characteristics. Tumor endothelial cells (TECs)
may originate from tissue resident or bone marrow derived
stem cells undergoing endothelial differentiation, or from
tumor stem cells that can produce both tumor cells andTECs.
These mechanisms suggest a contribution of vasculogenesis
to neoformed blood vessels in tumors [7].
Vasculogenic mimicry (VM) was first described in
aggressive melanoma by Maniotis et al. [3], who stated that
the generation of patterned melanoma microcirculation is
mediated by the tumor cells themselves and may function
independently of tumor angiogenic mechanisms during
various phases of tumor progression. The name was coined
to describe the formation of these channels by aggressive
tumor cells: vasculogenic, because the channels are not
formed from preexisting vessels, and mimicry, because
the channels are not true blood vessels, but merely mimic
the function of vessels [10, 11]. In fact, it consists in de
novo generation of microvascular channels by genetically
deregulated, aggressive tumor cells without endothelial
cell participation [10]. As shown by transmission electron
microscopy, in melanoma the “vascular channel” is lined by
a thin basal lamina corresponding to the wall of the vessel,
but no endothelial cells are detected. Most of these channels
seem to be connected to normal blood vessels [5].
In vessel cooption, known also as mosaic vessel formation,
in contrast with the prevailing view that most tumors and
metastases begin as avascular masses, evidence is presented
that a subset of tumors initially grows by coopting existing
host vessels. Vessels are surrounded, coopted by tumor cells,
and no sprouts are observed [5]. This coopted host vascula-
ture does not immediately undergo angiogenesis to support
the tumor but instead regresses, leading to a secondarily
avascular tumor and massive tumor cell loss. However, the
remaining tumor is rescued by robust angiogenesis at the
tumor margin [12]. The role of vessel cooption in tumori-
genesis is still debated. Vajkoczy et al. [13] in the results of
their study report the fact that the cellular organization of
the solid tumor component did not follow the organization
of the host blood vessels which clearly indicates that the
majority of tumor cells do not coopt host blood vessels.
According to the same authors, at this multicellular stage, the
tumor cells have already initiated their neovascularization by
inducing angiogenic sprouting from the microvasculature of
the adjacent host tissue.
Angiogenesis is the most studied form of neovascular
growth in cancer. As early as 1971, Judah Folkman proposed
the hypothesis that tumor growth is dependent on the
formation of new blood vessels. Angiogenesis is essential for
the development and evolution of neoplastic disease, as both
tumor growth and metastasis require persistent new blood
vessels and ongoing angiogenesis is essential for rapid expan-
sion of a tumor mass [6, 14]. Angiogenesis can be assessed as
intratumoral microvessel density (IMVD), which is related
to tumor aggressiveness, metastasis, and decreased patient
survival [14]; therefore, inhibition of tumor angiogenesis
would be an effective strategy to treat cancer [15]. In angio-
genesis, new capillaries originate from existing vessels [16].
Induction of angiogenesis is a discrete component of the
tumor phenotype, one that is often activated during the early,
preneoplastic stages in the development of a tumor [6]. In the
majority of cancers, vessel growth is not only stimulated, but
these vessels are also abnormal in almost all aspects of their
structure and function. Abnormal tumor vessels can also
impede the function of immune cells in tumors, as well as the
transport and/or distribution of chemotherapeutics and oxy-
gen. Interstitial hypertension, hypoxia, and acidosis—which
are all results of abnormal vessel structure and function—
create a favorable environment for tumor progression and
metastasis [8].
2. Different Mechanisms of Angiogenesis
It was originally considered that new blood vessel formation
in tumors only occurred after such a tumor became invasive.
However, it has been shown that angiogenic growth factors
are already present in preinvasive lesions [17]. Epidemio-
logical studies showed that patients bearing premalignant
lesions have a high risk to develop an invasive cancer, and
premalignant lesions can be found in almost all epithe-
lial organs. These lesions are characterized by disordered
proliferation, loss of cellular uniformity and architecture;
some seem to be reversible, but others are progressive, and
predictive factors of reversibility or progression are virtually
unknown [18]. Angiogenesis precedes overt tumor formation
during chemically induced carcinogenesis, suggesting that
tumor progression depends on a switch from a prevascular
to a vascular phase [6]. According to Folkman et al. [19],
angiogenic activity first appears in areas of hyperplasia
before the onset of tumor formation. Not all tumors are
angiogenic from the beginning of their natural evolution and
the angiogenic switch reflects the ability of the tumor and
inflammatory cells to secrete angiogenic factors in tumor
microenvironment [18]. Without the process of neovascu-
larization, tumors remain in their dormant, nonangiogenic
form, where proliferation is balanced with apoptosis, main-
taining these microtumors quiescent [20]. The activation of
the angiogenic switch takes place during the early stages
of tumor development, suggesting that the regulation of
angiogenesis is a discrete, potentially self-limiting step in the
pathway to many solid tumors [6].
Marked differences are suggested among different types
of solid tumors and among species in the promotion of
a switch of the angiogenic type, depending on the action
of proangiogenic factors or antiangiogenic inhibitors on
endothelial or stromal cells that subsequently form capillary
“sprouts” [4, 21, 22].
Sprouting angiogenesis is the first of two processes char-
acterizing angiogenesis [23], the second being intussuscep-
tive angiogenesis [24]. Sprouting angiogenesis is a process
through which a single endothelial cell, called the tip cell,
is selected from the vasculature, overcoming its quiescent
environment and forming a new vessel [25]. Activation of
sprouting is a relatively sluggish process in vivo, requiring
more than 24 h, and at least 3–5 days elapse before a new
capillary loop becomes perfused and is integrated into the
vascular system [23, 26].
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Figure 1: Angiogenetic sprouting: after stimulation with angiogenic factors, the quiescent vessel dilates and an endothelial cell tip cell is
selected. Stalk cells behind the tip cell proliferate, elongate, and form a lumen, and sprouts fuse with an adjacent vessel sprout to establish a
perfused neovessel, (from [8], modified).
The sprouting of new vessel segments, both in normal
organ development and in tumors, follows a well-defined
program that starts with degradation of basement membrane
on the side of the tumoral postcapillary venule situated close
to the angiogenic stimulus [23]; then the tip endothelial
cell migrates towards a chemoattractant angiogenic signal
constituted of growth factors that are secreted by the tumour
cells and their stroma [25] and proliferates forming solid
sprouts of endothelial cells connecting a neighboring vessel
and restructuring of the sprout into a lumen lined by endothe-
lial cells and integrated in the vascular network (Figure 1)
[23]. Because sprouting angiogenesis is an invasive process,
proteolytic activities are required. Proteolysis is largely medi-
ated by matrix metalloproteinases (MMPs), a family of zinc
containing calcium-dependent endopeptidases secreted by
various cell types [27]. The role of the metalloproteinase
MT1-MMP (membrane-type 1matrixmetalloproteinase) was
addressed in different cell types in terms of its ability to
regulate sprout formation [25]. Enzymes are needed not
only for the degradation of the basement membrane of
endothelial cells allowing invasion into the tissue, but also
for cell migration and removal of obstructingmatrix proteins
and for creating space in the matrix to allow generation of
endothelial cell tubules [28, 29]. MT1-MMP, other MMPs,
and the related ADAMs (a disintegrin and metalloproteinase
domain) modulate the balance between pro- and antiangio-
genic factors by activation andmodification of growth factors
and chemokines, ectodomain shedding with accompanied
receptor activation, shedding of cytokines from membrane-
bound precursors, and generation of (matrix) protein frag-
ments that inhibit or activate angiogenesis [29].
After migrating, endothelial cells proliferate during the
sprouting process in tumors; they maintain their basal-
luminal polarity and form a slit-like lumen that is continuous
with the lumen of the so-called mother vessel. Basement
membrane material is deposited continuously by the sprout
endothelial cells, whereas only the tip of the growing bud
is in contact with the collagenous connective tissue matrix
[30]. As the final step, proliferating pericytes of the mother
vessel migrate along the basement membrane of the sprout,
resulting in the maturation of the new vessel [30].
In contrast to endothelial sprouting, the other major
angiogenic mechanism is intussusceptive microvascular
growth, or intussusceptive angiogenesis, which is achieved by
intraluminal growth. Intussusceptive angiogenesis has been
described in a wide variety of normal and pathological condi-
tions, is faster, and does not depend primarily on endothelial
cell proliferation. It occurs within hours or even minutes,
does not primarily need endothelial cell proliferation, and can
expand to all existing capillary networks [1, 24]. Djonov et al.
(2001) demonstrated that inmammary tumors of neuT trans-
genic mice, both sprouting and intussusceptive angiogenesis
occur simultaneously in the same nodule. The transient
normalization of tumor vasculature may be explained on
morphogenic level by the angiogenic switch from sprouting
to intussusception. The switch to intussusceptive mode of
angiogenesis improves the perfusion of the tumormass as has
been shownby the decrease in hypoxia of the tumormass [31].
The concept of network expansion and vessel formation
was introduced by Caduff et al. [32] when they studied the
developing microvasculature in the postnatal rat lung. Obvi-
ously, this concept represented a newmode of angiogenesis—
an alternative to capillary sprouting. The capillary system
would expand “within itself.” The most appropriate term for
such a mechanism in histology was intussusception, and
thus this concept was named intussusceptional microvascu-
lar growth (IMG) [32]. This terminology was modified to
intussusceptive angiogenesis by Burri and Tarek [33], who
demonstrated the tissue posts to be pillars in the vascular
lumina of developing vessels by serial sectioning [24] (known
also as “nonsprouting or splitting angiogenesis”) [34].
The most characteristic feature of intussusceptive angio-
genesis in tumor tissues is thought to be the development of
protrusions or infoldings of the vessel wall within the lumen
[1] (Figure 2). According to Auguste et al. [5], two opposite
endothelial cell membranes make contact (“kissing” contact)
and interendothelial junctions develop at their edge. In the
middle of the kissing contact, membranes are thinned and
pressure induced by the cytoplasm opens them and separates
the two vessels.
The next step is the insertion of connective tissue col-
umns, called tissue pillars, into the lumen between the










Figure 2: Intussusceptive angiogenesis. Two opposite endothelial
cell membranes make contact (“kissing” contact) and interendothe-
lial junctions develop at their edge. Connective tissue columns,
called tissue pillars, grow into the lumen between the endothelial
contact, resulting in partitioning of the vessel lumen (from [28];
modified).
endothelial contact and the subsequent growth of these pil-
lars, resulting in partitioning of the vessel lumen and the con-
sequent increase in the density of the given capillary network
[5, 30]. Pillars, the hallmark of intussusceptive angiogenesis,
develop within capillaries, small arteries, and veins and
subsequently fuse, thus delineating new vascular entities or
resulting in vessel remodeling [24]. Intussusceptive angio-
genesis therefore splits an existing lumen into two [35].
The mechanism of connective tissue pillar formation during
tumor-induced intussusceptive angiogenesis can be summa-
rized as follows. First, transluminal endothelial bridges are
formed. Second, collagen bundles adjacent to the vessel are
seized by the abluminal side of a bridge forming endothelium.
Finally, maturation of these nascent pillars occurs via the
migration of pericytes and myofibroblasts into the collagen
core of the pillar and the deposition of additional collagenous
connective tissue by these cells. Tumor cells are able to both
incorporate into the pillars and contribute to their growth;
therefore, they help to dilute the newly formed capillary
network [30].
Intussusceptive angiogenesis may have different out-
comes depending on the location of the pillars, and different
subtypes are named as follows: intussusceptivemicrovascular
growth (IMG), which refers to the expansion of the capillary
bed, and intussusceptive arborization (IAR) that describes the
formation of the typical vascular tree, while intussusceptive
branching remodeling (IBR) denotes vascular remodeling
and adaptation to suit local perfusion requirements and
includes intussusceptive vascular pruning (IVP). Vascular
pruning is an essential adaptive mechanism resulting in the
regression of excessive vascular branches and the creation of
hierarchical, thermodynamically efficient angioarchitecture
[36]. It can be summarized as the formation of multiple
eccentric pillars at the bifurcation points and their subsequent
successive fusions, which leads to partial and later to total
luminal obstruction and separation (cutting-off) of one or
more of the affected daughter branches. At the initial stage,
intraluminal protrusions of endothelial cells lying at the
opposing sides of the vessel are formed. The contact between
them has to be established for the single pillar to emerge [36].
In the majority of cancers, vessel growth is not only
stimulated, but the new vessels are also abnormal for struc-
ture and function. These vessels are tortuous, irregularly
shaped, and hyperpermeable [37]. Tumor endothelial cells
protrude extensions into the lumen and form abluminal
sprouts, with leading tip cells penetrating deep into the tissue.
These endothelial cells are often leaky, have wide junctions,
and containmultiple fenestrations and other transendothelial
channels, resulting in haemorrhage and increased interstitial
fluid pressure, which limits perfusion [8, 37]. The base-
ment membrane shows conspicuous structural abnormali-
ties, including a loose association with endothelial cells and
pericytes, broad extensions away from the vessel wall, and
multiple layers visible by electron microscopy [38]. Tumor
pericytes are also implicated in the abnormal nature of tumor
vessels. Pericytes around tumor vessels are loosely attached
to endothelial cells, have abnormal shapes, or present long
cytoplasmic processes away from the vessel wall. Strategies
to enhance pericyte coverage may prevent tumor vessel
leakage, dilatation, and tortuosity and may promote vessel
stabilization and normalization [7].
Tumor blood flow is not only chaotic, but also stagnant
in places and, because of continuous vessel remodeling, it
is variable between different tumors, between the primary
cancer and its metastatic lesions, and within the same tumor
[39]. The tumor microenvironment, because of hypoxia, low
pH, and high interstitial fluid pressure, can alter the intrinsic
characteristics of tumor cells, resulting in a selection of tumor
clones and facilitated escape of neoplastic cells through leaky
vessels [37], favoring the metastasis.
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3. Mechanisms of Angiogenic Activation
Tumor-induced angiogenesis depends on the production of
pro-angiogenic growth factors by the tumor cells [6] and
involves a diverse array of molecules that includes both
those that regulate the maintenance and destruction of the
perivascularmilieu (which includes both extracellularmatrix
and perivascular cells) as well as those which stimulate
endothelial cell division and migration [12].
The first angiogenic growth factor, basic fibroblast growth
factor (bFGF), belongs to the FGF family. bFGF stimulates all
major steps in the angiogenesis cascade and is produced by
many cells, among which are macrophages and tumor cells.
Although FGF does not have a signal sequence that allows
regular secretion, it is released in the extracellular matrix
after which angiogenesis is initiated. bFGF is a pleiotropic
mitogen for growth and differentiation, known to be involved
in endothelial cell proliferation, extracellularmatrix degrada-
tion, endothelial cell migration, andmodulation of junctional
adhesion molecules [40].
The angiopoietin family, another important growth factor
family in angiogenesis, includes three members (in humans),
namely angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), and
angiopoietin-4 (Ang-4) that all bind to the endothelial
tyrosine kinase receptor Tie-2. The most remarkable charac-
teristic of this family is the opposing effect of the different
ligands binding to the same receptor. Ang-1 activates the
Tie-2 signalling while Ang-2 inhibits this activation. Ang-
1 is involved in endothelial cell migration, adhesion, and
the recruitment of pericytes and smooth muscle cells, while
Ang-2 is vessel destabilizer [40]. Ang-1 is produced by
numerous cell types including mural cells (pericytes, smooth
muscle cells), fibroblasts, and monocytes, thereby acting in
a paracrine manner; Ang-2 is almost exclusively produced
by endothelial cells [41]. The role of Ang-1 in tumor angio-
genesis is controversial. In fact, its overexpression stimulates
divergent responses depending on tumor type, ranging from
promotion to limitation of growth [42].
Ang-2 is the main angiopoietin ligand in tumors [4]. Its
levels are upregulated by hypoxia [43]. Ang-2 overexpression
in mammary carcinoma cells induces intratumoral hemor-
rhage and nonfunctional and abnormal blood vessels [44]. It
acts in connection to VEGF, and the functional correlation
of the coordinated VEGF/Ang-2 activity is an increase in
host vessel permeability, loss of blood-brain-barrier func-
tion in cerebral vessels, microvascular dilation, and sprout
formation. In the later stage of tumor development, Ang-2
and VEGFR-2 continue to be expressed at high levels by the
host and tumor microvasculature, which remain in a state of
angiogenic plasticity [13].
The role of inflammation and inflammatory cells in
tumor development and progression has been increasingly
studied. Circulating leukocytes, red blood cells, and platelets
participate in angiogenesis by VEGF secretion [45, 46],
and this explains angiogenesis in tumors of blood cells.
Besides VEGF, activated platelets also release other angio-
genic proteins, including FGF, insulin-like growth factor
1 (IGF-1), and platelet-derived growth factor (PDGF) as
well as Ang, stromal cell-derived factor-1 (CXCL12), MMP-
Figure 3: Figure 3: Dog. Mammary tumor. Cytoplasmic endothelial
(arrow) positivity of vessel walls, of stromal fibroblasts (arrowhead),
and of carcinoma cells (double arrows). Anti-VEGF immunohisto-
chemistry x63.
(metalloproteinase-) 1, MMP-2, and MMP-9 [47]. VEGF,
bFGF, epidermal growth factor (EGF), PDGF, and TGF-
𝛼, can also be produced by tumor associated macrophages
[48]. After recruitment and activation, macrophages secrete
a broad spectrum of growth factors, cytokines (such as IL-
1, IL-2, IL-6, IL-8, IL-12, and IL-17) [49], chemokines, and
matrix-degrading enzymes, which are directly involved in
the endothelial cell function and facilitate endothelial cell
migration via extracellular matrix remodeling. In a hypoxic
environment such as that in tumors, hypoxia tightly regulates
the expression of various pro-angiogenic chemokines in
macrophages, including CXCL12, C-C chemokine ligand 2
(CCL2), CXCL8, CXCL1, CXCL13, and CCL5 [48].
In the mosaic of cells and substances promoting angio-
genesis, an important role is played by cancer stemcells (CSC)
[50]. These cells are distinguished from other substances in
that they can reconstitute in a recipient animal a tumor that is
identical to the parental patient tumor and that can be serially
xenotransplanted indefinitely. CSC produce high levels of
VEGF in both normal and hypoxic conditions, leading to
a strong angiogenic response, which can promote tumor
growth [49].
Vascular endothelial cell growth factor (VEGF) or vascu-
lar permeability factor is the most studied in the stimulation
of angiogenesis. It increases the expression of MMPs and
plasminogen activators for the degradation of the extracel-
lular matrix and subsequently endothelial cell migration [51].
VEGF denotes a family of five relatedmammalian growth
factors: VEGFA (the prototype), VEGFB, VEGFC, VEGFD,
andPLGF (placental growth factor) [52].The role of this latter
is underestimated, even if it is known that activated endothe-
lial cells produce large amount of PLGF, thereby regulating
the VEGF mediated angiogenic switch [40]. Several of the
VEGF family of ligands and receptors, notably VEGFA, are
regulated by HIF (hypoxia-inducible factor) [53], linked to
the hypoxic condition present in the necrotic compartments
[54]. VEGF protein is synthesized and localized in the
cytoplasmic granules of neoplastic epithelial cells, endothelial
cells, and stromal cells, (Figures 3 and 4) indicating that both
autocrine and paracrine signaling induces proliferation of
endothelial sprouts [55, 56].
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Figure 4: Figure 4: Dog. Mammary tumor. Cytoplasmic positivity
(arrow) in carcinoma cells. Anti-VEGF immunohistochemistry x63.
4. Overview of Squamous Cell Carcinoma in
Humans, Dogs, and Experimental Animals
Squamous cell carcinoma (SCC) is the secondmost common
skin tumor in humans and dogs [57] following basal cell
carcinoma and mast cell tumor, respectively. In Sprague-
Dawley rats, SCC is the 2nd most common cutaneous
epithelial neoplasm [58–60], and inmice SCC has rarely been
reported since creosoted wooden cages have been discarded
[61]. In humans, cutaneous SCCs commonly arise directly
from or in close proximity to actinic keratosis [62]. Similarly,
actinic keratoses and SCCs often coexist in dogs [57]. In
experimental animals, actinic keratosis and SCC can be
induced by chronic UV radiation [63]. Genetic mutations
in the p53 tumor suppressor gene have been reported in
SCC in humans, dogs, and experimental animals [64–67].
Other mutations have been reported in humans and later
reproduced in experimental animal models, but are yet to be
found in dogs [67, 68].
5. Vascular Endothelial Growth Factor
Mediated Angiogenesis in Squamous
Cell Carcinoma
Angiogenesis is essential for the growth and metastases of
many malignant tumors including cutaneous squamous cell
carcinoma. Several studies have shown that VEGF plays an
important role in cutaneous malignancies. In human skin
VEGF is expressed at low levels within the normal epidermis.
The production of VEGF by normal keratinocytes can be
induced by many stimuli including the tumor promoter 12-
O-tetradecanoylphorbol-13 acetate (TPA), UV radiation, ker-
atinocyte growth factor, hypoxia, and transforming growth
factor-𝛼 [69–72]. The expression of VEGF is markedly
increased within epithelial tumors of the skin [73–75]. In
particular, cutaneous SCCs display intense and widespread
expression, with the highest expression in tumor cells close
to inflammatory foci [74]. Furthermore, the expression of
VEGF is higher in poorly differentiated SCCs compared to
well-differentiated tumors [76].
VEGF is also expressed in the normal canine epidermis
[77]. Only two studies examined the expression of VEGF in
canine cutaneous SCC. The expression of VEGF was found
in the majority of SCCs in both studies [78, 79]. Both studies
also reported an increase in VEGF expression level with the
advancement of histological grade with one study reporting
higher levels in SCC arising on the toe [78].
Several experimental animal models have been used to
study SCC. These include mice xenograft models, chemi-
cally induced SCC mice models, and genetically engineered
mice models [80–82]. In the cutaneous two-stage chemical
carcinogenesis mouse model, hyperplastic epidermal lesions
develop initially.These lesions progress to benign papillomas
first and later become squamous cell carcinomas [83]. The
progression of lesions in this model is associated with a
sequential increase in VEGF at the mRNA and protein level
[83]. Thus, similar to humans and dogs the expression of
VEGF in mice is low within the normal epidermis and
increases stepwise during carcinogenesis [83]. Moreover,
examination of the vasculature using the endothelial cell
marker CD31 has shown that vascular density increases con-
siderably in the early papilloma stage [84]. In more advanced
papilloma lesions, the vascular density stabilizes but the
size of the vasculature is increased [85]. The use of VEGF
transgenic mice models overexpressing VEGF in epidermal
keratinocytes, such as K6-VEGF and K14-VEGF transgenic
mice, has provided strong evidence for the involvement of
VEGF in angiogenesis [86, 87]. Compared to controls, these
VEGF transgenic mice show marked increase in vascular
density in the normal skin and in skin tumors. Furthermore,
these transgenic are more susceptible to two-step chemical
carcinogenesis [86, 87].
In dogs with cutaneous SCCs, one study reported a
significant difference in vascular density among different
histological grades with higher grade tumors having higher
vascular density [78]. Contrary to this finding, another study
failed to find a correlation between VEGF expression level
and tumor grade [79]. The disparity between the two studies
could be due to the difference in endothelial markers used
to assess vascular density. Additional studies, utilizing larger
sample size, are needed to examine the relationship between
VEGF and vascular density in canine cutaneous SCCs.
6. Autocrine VEGF Signaling in SCCs
An autocrine pathway involves the secretion of a ligand
which, consequently, engages a specific receptor on the same
cell surface and results in a signaling response that affects
cell function [88]. It is now clear that tumor cells acquire a
certain degree of self-sufficiency through autocrine signaling
pathways that facilitate their growth, survival, and invasion
[89]. One of the first indications that VEGF may exhibit
autocrine function in carcinoma was provided in a study
on invasive breast carcinoma cell lines. Lowering VEGF
expression by 50% using antisense oligonucleotides resulted
in a significant increase in apoptosis, even in the presence of
10% serum [90]. Similar to breast carcinoma, several studies
reported an autocrine role for VEGF in cutaneous SCCs.
Using the K5-SOS transgenic mouse model, in which mice
develop skin tumors spontaneously or after a skin wound,
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it has been shown that epidermal tumor cells of K5-SOS
transgenic mice express high levels of VEGF and its receptors
Flt1 and Nrp1 [91]. Deletion of VEGF in this mouse model
resulted in reduced tumor development, vascular density,
and tumor proliferation [91]. The main source of VEGF in
the skin is epidermal keratinocytes [92], although other cell
types including macrophages and fibroblasts are known to
produce VEGF [93, 94]. Several VEGF receptors have been
identified on the surface of epidermal keratinocytes including
VEGFR-1, VEGFR-2, andNRP-1 [95]. VEGFR-1 has also been
localized to human and mouse skin tumors and in SCC
cell lines [91]. VEGFR-1 expression was detected in K5-SOS
mice and deletion of VEGFR-1 in these mice resulted in
decreased development of papilloma and decreased tumor
cell proliferation. Furthermore, SCC cell lines in which
VEGFR-1 was deleted exhibited lower cell proliferation [91].
These studies point to an autocrine role of VEGF in skin
carcinogenesis in whichVEGF results in enhanced tumor cell
proliferation by binding to VEGFR-1.
In dogs VEGFR-2 was detected in a few canine tumors
including cutaneous SCC, simple mammary gland adenocar-
cinoma, fibrosarcoma [59, 60, 79], apocrine gland anal sac
adenocarcinoma, and thyroid carcinoma [96]. Interestingly,
the expression of VEGF and VEGFR-2 in canine cutaneous
SCC was positively correlated with tumor cell proliferation
index [79]. This indicates that VEGF may enhance tumor
cell proliferation through an autocrine loop which involves
VEGFR-2. Additional in vitro and in vivo studies are needed
to examine the autocrine role of VEGF and the roles of its
receptors in canine cutaneous SCC.
7. Angiogenesis in Canine Mammary Tumors
Mammary tumor growth forces cells to face the same increas-
ing demand for oxygen, glucose, amino acids, and waste
exchange as do normal mammary cells during development,
different oestrus phases, and lactation [97]. As in normalcy,
such a demand drives angiogenesis, the process whereby
new blood vessels sprout from the existing vasculature [98].
Several molecules such as cell surface receptors, growth
factors, and enzymes are involved in this process.
Tumor-associated angiogenesis and lymphangiogenesis,
the process whereby lymphatic vessels are generated, are
crucial in mammary tumor progression. Tumor vasculature,
together with the lymphatic system, is themain route through
which BMDCs (bone marrow-derived dendritic cells) infil-
trate the tumors and tumor cells themselves are able to evade
from primary sites and systemically disseminate [99].
The VEGF and its receptors VEGFR1 and VEGFR2
are leading players in angiogenesis [100]. The literature is
somewhat conflicting in what regards VEGF expression in
CMT (canine mammary tumors) and its relationship to the
biological behavior of this type of tumors. This is most
likely due to the antibodies used which recognize distinct
splicing forms of the protein [54, 56, 101, 102]. Other possible
explanation for the inconsistency of the results lays on the fact
that VEGF-A has alternative splicing forms some of which are
more prevalent than others and correlate to worse prognosis
in different types of cancer.These distinct isoforms are known
to induce distinct vessel conformation and type of circulation.
The receptor tyrosine kinase (RTK) activity of VEGFR1 is
also dependent on the isoform present [103]. Thus, given
that distinct splicing forms differ in their function, this may
account for the differences in findings from different groups
studying VEGF in CMT. Regardless of this, all authors find
a high expression of VEGF in CMT cells [54, 56, 101, 102].
Interestingly, work in CMT showed an upregulation of VEGF,
assessed by its level of intensity, at the invasive front of the
primary tumor cells and also in cells surrounding necrotic
areas. The latter pointing to a potential role for the harsh
microenvironment found in these areas in regulating VEGF
[56]. These are hypoxic regions of the tumors in which the
cells suffer from lack of oxygen but also glucose and amino
acids deprivation, being that the lactate concentration is high
at all times. Low levels of oxygen trigger stabilization of the
hypoxia-inducible factor (HIF) 𝛼 subunits. In the absence of
oxygen, the 𝛼 subunits are not hydroxylated and hence are no
longer targeted for degradation by the proteosome. Stabilized
HIF-1 𝛼 upregulates several genes in order to promote
survival under hypoxic conditions. Among these is theVEGF.
Remarkably, in a subsequent work, de Oliveira et al. [104]
have observed that the epidermal growth factor receptor
(EGFR) is significantly associated with the presence of necro-
sis in CMT and was found to be overexpressed in these same
stress-inducing areas. EGFR has a well-established role in
mammary angiogenesis and was found to be overexpressed
in tumors which relapse to antiangiogenic therapy [105, 106].
Other HIF-1 𝛼 target genes interestingly expressed in
CMT are galectin-1 and galectin-3. Galectin-1 and galectin-
3 are members of galectins, a carbohydrate-binding family
of proteins. These are involved in cell survival to anoikis,
cell-cell, and cell-ECM (extra-cellular matrix) adhesion and
are also crucial players in angiogenesis. Galectin-3 is known
to be chemoattractant to endothelial cells and to stimu-
late neovascularization in vivo, therefore contributing to
tumor angiogenesis, an essential step formetastatic spreading
[107]. Galectin-3 is in accordance overexpressed in necrosis-
surrounding cells both in primary and in metastatic CMT
lesions despite downregulated in other tumor areas. It is of
note that galectin-3was also found to induceVEGF in human
breast cancer cells and hence promote angiogenesis [108].
Tumor cells secrete galectin-1 in order to induce angiogenesis
[109]. This galectin is overexpressed both in tumor cells and
stroma of CMT [110]. Galectin-1 was interestingly recently
found to be the target of the potent angiogenesis inhibitor
Anginex [111].
ECM is deposited to form a basement membrane to
surround the blood vessels during tumor angiogenesis.
Importantly, however, the basement membrane of the tumor
vasculature is more porous and leaky than normal [112,
113], which facilitates tumor cell metastasis and immune
cell infiltration and promotes cancer progression [114, 115].
The ECM plays a crucial role in blood vessel formation. In
addition to guiding endothelial cell migration and branching,
ECM and its fragments may be involved in endothelial
cell survival and proliferation to supply cellular building
blocks for vessel growth [116]. ECMbiomechanical properties
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appear to play an especially important role in angiogenesis.
Indeed, vascular networks with markedly distinct branching
patterns have been observed when endothelial cells are
grown on matrix with different elasticity [117]. Among other
changes, ECM biomechanical properties may be influenced
by posttranslational modifications on ECM proteins such as
altered glycosylation, a common feature in cancer. Malignant
CMT displayed an altered ECM glycosylation which corre-
lated with the downregulation of GLT25D1, a 𝛽 (1-O) galac-
tosyltransferase that modifies collagen [110]. In parallel with
the downregulation of galectin-3, malignant CMT displayed
an overall loss of galectin-3-binding sites in the ECM and
focal expression of galectin-3-binding sites mainly detected
in intravascular tumor cells and endothelium. Interestingly,
GLT25D1 mRNA expression was strikingly downregulated
in malignant CMT-U27 compared with the benign cell line,
and its expression was further decreased in a galectin-
3 knockdown CMT-U27 cell line. ECM components are
involved in cellular morphogenesis, including vessel lumen
formation [118] and other aspects of tubulogenesis during
tumor angiogenesis [98]. Moreover, ECM fragments, derived
from collagens types IV and XVIII, have potent stimulatory
or inhibitory effects on angiogenesis. These are likely to
collaborate with other pro- or antiangiogenic factors, includ-
ing VEGF, to determine the architecture of vessel-branching
[119]. It is of note that, to initiate vascular branching, vessel
basement membrane ECM needs to be fragmented and
removed. This process is most likely performed by MMPs
which are expressed by invading endothelial cells or can be
secreted by the tumor cells. MMPs are also required for the
top edge of an endothelial branch, to overcome and progress
throughout the stromal tissue towards distressed cells [29,
120]. MMP2 and MMP9 are two members of this family well
known to contribute to angiogenesis. Benign CMT present
MMP-2 immunoreactivity in the myoepithelial cells lining
the basement membrane of tubuloalveolar structures, while
malignant CMT showed mainly diffuse expression in neo-
plastic cells [121]. Stromal-associated MMP9 which mediates
tumor-induced angiogenesis showed higher expression in
highly proliferative CMT and in CMT with invasive growth,
high histologic grade, and metastatic capacity [122].
The serine protease urokinase-type plasminogen activa-
tor (uPA) involved in the control of extracellular matrix
turnover is involved in vascular remodeling and was also
shown to be implicated in the stimulation of angiogenesis
[123]. Malignant CMT expressed significantlymore uPA than
benign tumors. In malignant CMT, high uPA stromal expres-
sion was significantly associated with larger tumor size, high
Ki-67 expression, invasive growth, high histological grade,
regional lymph node metastases, development of distant
metastases, and lower overall survival (OS) and disease-free
survival (DFS) [121].
Antiangiogenic therapy for breast cancer has raised a
great deal of controversy within the scientific community
over the last years. For instance, bevacizumab blocks VEGF,
its association with paclitaxel doubles the time of human
breast cancer progression although not affecting the patients’
overall survival. Therefore there is resistance to antiangio-
genic therapy. It is now understood that this type of therapy
induces hypoxia and that hypoxia-dependent pathways lead
to decreased cell death [124]. The antiangiogenic therapy
leads for a while to decreased tumor growth but afterwards
relapse occurs.This type of relapse is thought to be dependent
on two distinct mechanisms (1) altered cell behavior with
increased invasion and metastatic capacity and (2) reneovas-
cularization.The firstmechanism can be explained by the fact
that by inhibiting VEGF hypoxia is induced but there is also
an increase inMet phosphorylationwhich is usually inhibited
by VEGF. Increased Met signaling leads to an upregulation
of epithelial mesenchimal transition (EMT) related genes
such as Snail, N-cadherin, vimentin, and CD44. The second
mechanism relates to a hypoxia-induced increase in tumor-
infiltrating bone marrow derived cells, vascular progenitor
cells able to differentiate into endothelial cells, implicated in
antiangiogenic treatment resistance [125, 126].
In conclusion, there are several interdependent pathways
driving angiogenesis in cancer in general and in CMT in
particular. This knowledge is of the utmost importance
when considering future antiangiogenic therapies for CMT
management in veterinary oncology.
8. Angiogenesis Models for Preclinical
Drug Studies
Preclinical drug studies theoretically should define whether
a particular potential therapy has activity against tumors
with the appropriate drug target, and whether or not activity
observed in these models can be extrapolated to humans.
The interpretation of data from preclinical studies is often
perceived as a bottleneck in drug development; thus, the
selection of appropriate preclinical angiogenesis models with
reproducible activity can lead to subsequent success in the
clinic.
The emergence of targeted therapy has resulted in the
need for translational preclinical drug assessment strategies
in an attempt to bridge the gap between preclinical models
and clinical efficacy. Existing models that have been used
in the development of traditional cytotoxic drugs should be
reevaluated and refined for these newer “molecularly targeted
drugs.” It remains critical to choose appropriate angiogenesis
assays to evaluate the efficacy of novel drug compounds and
to identify potential targets within the angiogenic disease to
enable the proper translation of data from preclinical to the
clinic testing.The principle angiogenesis assays include those
for endothelial cell proliferation, differentiation, migration,
and coculture models in vitro; vessel outgrowth from organ
cultures such as the ex vivo rat aortic ring assay; and in
vivo assays such as chick chorioallantoic membrane (CAM),
zebrafish, sponge implantation, corneal, dorsal air sac, cham-
ber, and tumor angiogenesis models (reviewed in [127]).
With respect to animal models, two of the most com-
monly used for preclinical testing are tumor xenograftmodels
(cell line xenograft or patient-derived xenograft), which
involves transplantation of human or syngenic mouse tumor
cells either subcutaneously or at a relevant orthotopic site
in immunocompromised mice, and genetically manipulated
mice that develop spontaneous lesions (genetically engi-
neered mouse models (GEMMs)), which involves genetic
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engineering to introduce genomic alterations that drive can-
cers of interest, ideally confined to the relevant tissue. When
choosing amousemodel for preclinical testing, consideration
is given to the tumor microenvironment targeted by the
drug, whether the drug is intended for early-stage versus late-
stage therapy and whether modeling the metastatic spread is
necessary. GEMMs have been especially effective for studying
the early events in tumorigenesis; however, they have not
replaced xenograft models as reliable clinically predictive
tools for examining the efficacy of therapeutic approaches
to treat metastatic disease. After the Rip1-Tag2 tumor model
was characterized as highly angiogenic [19], this and other
GEMMs were used extensively to evaluate antiangiogenic
therapies in vivo. While many of these models show single-
agent activity, predicting the clinical activity and efficacy of
antiangiogenics from animal data has proven challenging
since the translation of the single-agent activity has not been
seen in clinical trials targeting advanced metastatic disease
with the exception of renal cell, hepatocellular, and ovarian
carcinoma [128]. For example, TNP-470, a synthetic analog
of the antiangiogenic agent fumagillin, exhibited significant
tumor regression in the Rip1-Tag2 model as a single agent
[129]; however, its efficacy in humans was very limited,
due to its short half-life and neurotoxic effects [130]. Early
preclinical studies have shown that monoclonal antibodies
(mAbs) targeting VEGF-A suppress growth of several human
tumor xenograft models [131]. Other antiangiogenic agents
including mAbs against VEGFR2, soluble VEGF receptors,
and small-molecule inhibitors of the VEGF receptor tyrosine
kinases (RTKs) were also found to inhibit tumor growth
in xenografts and GEMMs [128]. While these inhibitors
demonstrated strong single-agent activitywhen the treatment
was initiated at early stages of tumorigenesis, most clinical
trials have been conducted in patients with advanced disease.
These VEGF pathway inhibitors have generally proven clin-
ically efficacious, not broadly as single agents, but rather in
combinations with chemotherapy that is cancer type-specific.
Indeed experience with experimental therapeutics in the
Rip1-Tag2model over time suggests that rational trial design
combined with more specific drug targets can improve the
predictive power of preclinical studies. As advances in cancer
genomics lead to more pharmacogenetics testing, preclinical
model systems need to continually be refined to define and
validate biomarkers to aid in patient selection and identify
antiangiogenic predictivemarkers of response and resistance.
Careful extrapolation of preclinical data in an era of increas-
ingly specific agents, more sophisticated animal models, and
increased understanding of the molecular drivers of cancer
is required. Successful translation of preclinical data to the
clinic has been demonstrated with the approval of several
antiangiogenic agents over the last decade.
9. Clinically Approved Antiangiogenic
Therapies
The angiogenic pathway has been a valid target for anticancer
drug development and VEGF has become the primary
antiangiogenic drug target. Investigation of hundreds of
potential angiogenesis inhibitors resulted in the approval
of bevacizumab (VEGF neutralizing antibody) by the U.S.
Food and Drug Administration as the first antiangio-
genic agent. Bevacizumab is approved in combination with
chemotherapy or cytokine therapy for advanced metastatic
cancers including colorectal cancer (CRC), nonsquamous
non-small-cell lung cancer (NSCLC), and renal cell cancer
(RCC). Bevacizumab monotherapy is approved for recur-
rent glioblastoma. Subsequent antiangiogenic agent FDA
approvals include the multitargeted pan-VEGF receptor
(VEGFR) tyrosine kinase inhibitors (TKIs) that target dif-
ferent parts of the angiogenic pathway: sorafenib for the
treatment of advanced RCC and unresectable hepatocellular
carcinoma; sunitinib for metastatic RCC, gastrointestinal
stromal tumor, and advanced pancreatic neuroendocrine
tumors; pazopanib for metastatic RCC and advanced soft
tissue sarcoma (with orphan drug status designation for
this indication); vandetanib for advanced medullary thyroid
cancer; and axitinib for advanced RCC. More recently,
ziv-aflibercept was approved for use in combination with
chemotherapy for metastatic CRC. Ziv-aflibercept, a protein
comprised of segments of the extracellular domains of human
VEGFR1 and VEGFR2 fused to the constant region (Fc) of
human immunoglobulin G (IgG1), functions as a soluble
decoy receptor that neutralizes VEGFs.
In general, these VEGF/VEGFR inhibitors provide mod-
est clinical benefit in terms of prolonging progression-free
survival (PFS) or overall survival (OS) of cancer patients
with a median duration of response in weeks to months.
Moreover, clinical experience with bevacizumab has proven
to be rather perplexing with improvement in PFS but little to
no benefit in OS. Of the 16 pivotal phase III trials conducted
with bevacizumab in solid tumors only threewere positive for
OS first-line mCRC [132], second-line mCRC [133], and first-
line recurrent/advanced NSCLC [134]. This concern made
headlines in 2011 when the FDA rescinded the approval of
bevacizumab for the treatment of breast cancer following
the failure of two phase III clinical trials to demonstrate an
improvement in OS for first-line breast carcinoma [135, 136].
10. Combination Therapies
Tumor angiogenesis is a highly complex process involving
multiple growth factors and their receptor signaling pathways
as well as key cellular players in the microenvironment such
as pericytes, endothelial cells, and bone marrow-derived
precursors. Based on current evidence, effective therapy will
probably rely on a combination approach that involves simul-
taneous targeting of multiple angiogenic pathways coupled
with cellular targets in themicroenvironment.Whether other
targeted agents exhibit beneficial effects when combined with
VEGF inhibitors remains to be investigated; however, the
use of targeted agents combined with conventional therapy
is intended to increase tumor response without significant
increases in toxicity.
A number of studies have shown that antiangiogenic
agents in combination with chemotherapy or radiotherapy
result in additive or synergistic effects. Several models have
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been proposed to explain the mechanisms responsible for the
chemosensitizing effects of antiangiogenic therapy [137]. One
hypothesis is that antiangiogenic therapy may normalize the
tumor vasculature, thus resulting in improved oxygenation,
better blood perfusion, and, consequently, improved delivery
of chemotherapeutic drugs [37]. A second model suggests
that chemotherapy delivered at low doses and more frequent
intervals with no extended drug-free break periods (also
called metronomic chemotherapy) preferentially damages
endothelial cells in the tumor neovasculature [138, 139],
suppresses circulating endothelial progenitor cells [140, 141],
sustains antiangiogenic activity, and reduces acute toxic-
ity [142]. Finally, the third model addresses the use of
antiangiogenic drugs to slow down tumor cell repopula-
tion between successive cycles of cytotoxic chemotherapy
[143]. This model underscores the importance of timing and
sequence in achieving the maximal therapeutic benefit from
combination therapies. Nonetheless, it remains a challenge to
determine why bevacizumab has proven largely ineffective as
a single agent whereas VEGFR TKIs have repeatedly failed
in randomized phase III trials when used in combination
with chemotherapy. Additionally, vascular disrupting agents
which aimed at collapsing the existing vascular structures in
combination with traditional antiangiogenic agents may fur-
ther improve the overall antitumor effect [144, 145]. Ongoing
studies will need to evaluate the most effective combination
of antiangiogenic agents with other targeted therapies and/or
conventional therapies in order to improve clinical outcomes.
11. Challenges to Antiangiogenic Therapy
11.1. Surrogate Markers of Tumor Angiogenesis and Antiangio-
genicTherapy. Antiangiogenic therapy has fostered the quest
for surrogate markers of response or resistance to assess and
monitor the clinical effects of these inhibitors.The lack of val-
idated biomarkers to date remains a challenge, thereby limit-
ing the successful use of antiangiogenic therapy in the clinic.
Surrogate markers are important for guiding the clinical
development of these agents and to select patients most likely
to benefit from this therapeutic approach.Anumber of candi-
date biomarkers including genetic, tissue, imaging, and circu-
lating biomarkers are emerging that need to be prospectively
validated [146, 147]. Several mechanisms are currently being
investigated and include tumor biopsy analysis, microvessel
density, noninvasive vascular imaging modalities (positron
emission tomography, dynamic contrast-enhanced MRI),
and measuring circulating biomarkers (levels of angiogenic
factors in serum, plasma, or urine; circulating endothelial
cells and their precursors) [148].
Recent research efforts have focused on identifying
genetic and toxicity biomarkers to predict which patients
will benefit from anti-VEGF/VEGFR therapy and identify
patients at risk of adverse events. The existence of VEGF
single nucleotide polymorphisms (SNPs) and their asso-
ciation with clinical outcome may be predictive markers
of response to bevacizumab. In a metastatic breast cancer
study involving patients being treated with paclitaxel and
bevacizumab (E2100 trial), SNP analysis demonstrated that
the VEGF-2578 AA and VEGF-1154 AA genotypes predicted
an improved median overall survival, whereas the VEGF-
634 CC and VEGF-1498 TT variants predicted protection
from grades 3-4 hypertension in the combination treatment
arm [149]. Another potential candidate surrogate marker is
hypertension, one of the most common toxicities in patients
taking VEGF inhibitors. The degree of hypertension can
serve as a biomarker of survival and show predictive value
for antitumor efficacy in patients after bevacizumab or TKI
treatment. In the same E2100 trial, patients who experienced
grade 3 or 4 hypertension survived significantly longer,
although hypertension was seen in patients with the VEGF-
634 CC and VEGF-1498 TT genotypes [149].
Additional biomarkers of response to antiangiogenic
therapy include measuring circulating elevated VEGF and
placental growth factor levels [146], while biomarkers of
resistance include circulating basic fibroblast growth factor,
stromal cell-derived factor 1𝛼, and viable CECs increased
when tumors escaped treatment [150]. If validated, these
findings could help select for subgroup of patients who may
benefit from antiangiogenic therapy and lead the way to
possible future personalizing of antiangiogenic therapy.
11.2. Resistance to Antiangiogenic Therapy. The clinical effi-
cacy of angiogenesis inhibitors has recently been met with
numerous phase III failures that showed modest survival
benefits because tumors elicit evasive resistance [151]. Under-
standing the resistance mechanisms of antiangiogenic ther-
apy is essential to overcome the limited effectiveness of
VEGF-pathway inhibitors. Resistance to VEGF pathway-
inhibitors may be observed in late stage tumors when
tumors regrow during treatment, after an initial period of
growth suppression from these antiangiogenic agents. This
resistance involves reactivation of tumor angiogenesis and
increased expression of other pro-angiogenic factors. As the
disease progresses, it is possible that redundant pathways
might be implicated, with VEGF being replaced by other
(pro)angiogenic pathways, warranting the addition of a sec-
ond angiogenesis inhibitor that would target these secondary
growth factors and/or their activated receptor pathways
or the use of a multitargeted pan-VEGFR TKIs. However,
resistance to these drugs eventually occurs implicating the
existence of additional pathways mediating resistance to
antiangiogenic therapies. Whether the administration of
angiogenic drugs at earlier stages of the diseasemay be amore
effective and beneficial approach remains to be determined.
Moreover, tumor cells bearing genetic alterations of the p53
genemay display a lower apoptosis rate under hypoxic condi-
tions, thereby reducing their reliance on vascular supply and
responsiveness to antiangiogenic therapy [152]. The selection
and overgrowth of tumor-variant cells that are hypoxia
resistant, and thus less dependent [152] on angiogenesis
and vasculature remodeling resulting in vessel stabilization
[153], could also explain the resistance to antiangiogenic
drugs. Other possible mechanisms for acquired resistance
to antiangiogenic drugs include tumor vessels becoming
less sensitive to antiangiogenic agents, tumor regrowth via
rebound revascularization, and vessel cooption [125, 154–
158]. Perhaps one of the most intriguing finding is that
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although endothelial cells are presumed to be genetically
stable, they may under some circumstances harbor genetic
abnormalities and thus acquire resistance as well [159, 160].
Recent studies report that antiangiogenic therapies
induce primary tumor shrinkage and inhibit tumor progres-
sion but can also initiate mechanisms that promote tumor
invasiveness andmetastasis [158, 161, 162].Thesemechanisms
of resistance to antiangiogenic therapy involve tumor and
host-mediated pathways, allowing for differential efficacy
in different stages of disease progression [158]. Specifically,
antiangiogenic drug resistance mechanisms involve path-
ways mediated by the tumor, whether intrinsic or acquired
in response to therapy or by the host, which is either
responding directly to therapy or indirectly to tumoral cues.
Angiogenesis inhibitors often cause tumor vessels to regress
resulting in vessel normalization. This vascular pruning can
also cause intratumoral hypoxia, which in turn activates
the hypoxia-inducible 1 factor alpha (HIF-1alpha) and HIF-
mediated pathways to promote invasion and metastasis from
the tumor [163]. Moreover, several reports have implicated
a critical role for hypoxia and HIF in cancer stem cell
(CSC) proliferation, self-renewal, and maintenance [164].
The tumor-initiating properties and metastatic potential of
CSCs make them key drivers of tumor growth and therapy
resistance. Indeed in the recent study, Conley and colleagues
demonstrated that hypoxia induced by the administration
of angiogenesis inhibitors might accelerate tumor growth
and metastasis by increasing the CSC population [165]. This
CSC niche may be responsible for mediating tumor metas-
tasis and resistance to cancer treatments. Taken together,
antiangiogenic therapy can enhance tumor invasiveness and
metastasis to facilitate and/or accelerate disease in micro-
scopic tumors, hence resulting in minimal overall survival
advantage. Understanding the mechanisms of resistance,
whether intrinsic or acquired, is essential for developing
strategies that will allow for optimal exploitation of the
potential of angiogenesis inhibitors. It is equally important
to identify surrogate markers of resistance to monitor the
development of evasive resistance to angiogenesis inhibitors,
thereby rendering this therapy more effective in the future.
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